Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-12-01T09:02:05.548Z Has data issue: false hasContentIssue false

Editor's Preface: Antidepressants of the Future

Published online by Cambridge University Press:  06 August 2018

R.G. Priest*
Affiliation:
Academic Department of Psychiatry, St Mary's Hospital, London, UK

Extract

Existing antidepressants are unsatisfactory: they have limited efficacy, side-effects are a problem, and there is an appreciable degree of toxicity. However, nonpharmacological, psychological approaches to the treatment of depression also have their own drawbacks, so that the search for better antidepressant compounds continues.

Type
Research Article
Copyright
Copyright © 1989 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Altamura, A.C., Montgomery, S.A. & Wernicke, J.F. (1986) The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. British Journal of Psychiatry, 153 (suppl. 3), 109112.CrossRefGoogle Scholar
Benfield, P. & Ward, A. (1986) Fluvoxamine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs, 32, 313334.Google Scholar
Nutt, D. & Glue, P. (1989) Monoamine oxidase inhibitors: rehabilitation from recent research? British Journal of Psychiatry, 154, 287291.CrossRefGoogle ScholarPubMed
Priest, R.G. & Woolfson, G. (1986) In Handbook of Psychiatry (8th edn). London: Heinemann Medical.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.